Results 21 to 30 of about 74,294 (341)

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment

Cancer Communications, Volume 42, Issue 12, Page 1387-1402, December 2022., 2022
Abstract Background Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health‐related quality of life (HR‐QoL) after total therapy, which included allogeneic hematopoietic stem cell transplantation ...
Chen‐hua Yan, Yu Wang, Yu‐qian Sun, Yi‐fei Cheng, Xiao‐dong Mo, Feng‐rong Wang, Yu‐hong Chen, Yuan‐yuan Zhang, Ting‐ting Han, Huan Chen, Lan‐ping Xu, Xiao‐hui Zhang, Kai‐yan Liu, Xiao‐jun Huang   +13 more
wiley   +1 more source

Molecular and cellular paradigms of multidrug resistance in cancer

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, Vishal Kumar Gupta, Shiv Govind Rawat, Ajay Kumar, Chandramani Pathak   +6 more
wiley   +1 more source

Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI

Hematological Oncology, Volume 40, Issue 5, Page 1041-1055, December 2022., 2022
Abstract The medium‐dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo‐HSCT) for acute lymphoblastic leukemia (ALL).
Mari Morita‐Fujita, Yasuyuki Arai, Tadakazu Kondo, Kaito Harada, Naoyuki Uchida, Takashi Toya, Yukiyasu Ozawa, Takahiro Fukuda, Shuichi Ota, Makoto Onizuka, Yoshinobu Kanda, Yumiko Maruyama, Satoru Takada, Toshiro Kawakita, Takahide Ara, Tatsuo Ichinohe, Takafumi Kimura, Yoshiko Atsuta, Shinichi Kako   +18 more
wiley   +1 more source

The histological changes induced by Cytarabine on rabbits livers (with and without vitamin E administration) [PDF]

Iraqi Journal of Veterinary Sciences, 2020
The present study was intended to determine the histological changes induced by Cytarabine drug on the structure of rabbit's livers and the protective effects of vitamin E on these histological changes.
Saif Al-Jammas, Ayad Al-Saraj
doaj   +1 more source

A conservative treatment for eosinophilic cystitis

IJU Case Reports, Volume 6, Issue 1, Page 8-12, January 2023., 2023
Introduction Eosinophilic cystitis is a rare condition which causes common symptoms and may mimic other conditions. Eosinophilic cystitis has several causes such as hypereosinophilic syndrome, inflammatory diseases, neoplasia, parasites or fungal infection, IgE‐related diseases, Drug Reaction and Eosinophilia and Systemic Symptoms (DRESS) syndrome, or ...
Franco Alchiede Simonato, Nicola Pavan, Mirko Pinelli, Gabriele Tulone, Rosa Giaimo, Anna Martorana, Alchiede Simonato   +6 more
wiley   +1 more source

Primary diffuse large B cell lymphoma of the prostate in a patient with HIV infection

IJU Case Reports, Volume 6, Issue 1, Page 30-32, January 2023., 2023
Introduction Primary prostate lymphomas are very rare; however, the incidence of malignant lymphoma is high among HIV‐infected patients. Herein, we report a case of primary diffuse large B‐cell lymphoma (DLBCL) of the prostate in an HIV‐infected patient. Case presentation A 47‐year‐old man presented with miction pain and back pain.
Takashi Ujiie, Taketo Kawai, Tomoyuki Kaneko, Tadashi Yamamoto, Yasutoshi Oshima, Mutsuo Fujikura, Nobu Akiyama, Yuko Sasajima, Haruko Tashiro, Tohru Nakagawa   +9 more
wiley   +1 more source

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

mBio, 2018
Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients.
Marion Gruffaz, Shenghua Zhou, Karthik Vasan, Teresa Rushing, Qing Liu Michael, Chu Lu, Jae U. Jung, Shou-Jiang Gao   +7 more
doaj   +1 more source

Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. [PDF]

PLoS ONE, 2011
BACKGROUND: Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for treating AML.
Xuelian Xu, Chengzhi Xie, Holly Edwards, Hui Zhou, Steven A Buck, Yubin Ge   +5 more
doaj   +1 more source

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Journal of Clinical Oncology, 2018
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells.
J. Lancet, G. Uy, J. Cortes, L. Newell, Tara L. Lin, E. Ritchie, R. Stuart, S. Strickland, D. Hogge, S. Solomon, R. Stone, D. Bixby, J. Kolitz, G. Schiller, M. Wieduwilt, D. Ryan, A. Hoering, Kamalika Banerjee, M. Chiarella, A. Louie, B. Medeiros   +20 more
semanticscholar   +1 more source